Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem Oncology develops and commercializes oncology medicines for RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S. for KRAS-mutated recurrent low-grade serous ovarian cancer and reports commercial updates, product revenue, and medical-conference data for the avutometinib and defactinib combination.
Recurring VSTM news also covers the company’s small-molecule pipeline, including RAF/MEK inhibition, FAK inhibition, and VS-7375, an oral KRAS G12D inhibitor studied in KRAS G12D-mutant solid tumors. Company updates commonly include clinical-trial analyses from RAMP studies, preclinical research presentations, FDA-related treatment context, patient advocacy resources for LGSOC, executive and employee equity grants, and quarterly financial results.
Verastem Oncology (Nasdaq: VSTM) will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 a.m. ET in New York.
A live webcast and a replay (available for about 90 days) will be hosted on Verastem’s website under “Events & Presentations.”
Verastem Oncology (Nasdaq: VSTM) appointed Michael P. Bailey to its Board of Directors, effective after Robert Gagnon’s term ended on May 21, 2026. Bailey brings over 30 years of global pharma and biotech leadership, including leading AVEO’s sale to LG Chem and commercializing oncology drugs such as ERBITUX.
According to Verastem, his expertise is expected to support growth of AVMAPKI FAKZYNJA CO-PACK and advance VS-7375, an oral KRAS G12D (ON/OFF) inhibitor targeting cancers with no approved therapies.
Verastem Oncology (Nasdaq: VSTM) will present at two investor conferences in New York City in May 2026. Management participates in the HCW 4th Annual BioConnect Investor Conference on May 19 and the RBC Global Healthcare Conference on May 20, with live and archived webcasts available.
Verastem Oncology (NASDAQ: VSTM), STAAR Low-Grade Serous Ovarian Cancer Foundation, and Not These Ovaries launched the LGSOC Resource Guide on May 8, 2026 for World Ovarian Cancer Day. Available at www.LGSOCAwarenessDay.org, the guide aggregates educational materials, community resources, and advocacy content for patients, caregivers, and clinicians focused on low-grade serous ovarian cancer.
The guide compiles resources from dozens of organizations, covers diagnosis, treatment, fertility, survivorship, and caregiver support, and notes that content may become outdated as research evolves.
Verastem Oncology (Nasdaq: VSTM) reported Q1 2026 results and program updates on May 7, 2026. Net product revenue was $18.7M. Cash, cash equivalents and investments totaled $181.7M with an expected runway into the first half of 2027. The company initiated three Phase 2 TARGET-D trials for VS-7375 and expects TARGET-D 101 early data in 1H 2026 and mature data in 2H 2026.
RAMP 201J in Japan showed a confirmed ORR of 38% (57% in KRAS-mutant patients). Operating expenses and R&D increased in Q1.
Verastem Oncology (Nasdaq: VSTM) launched the Reimagine Recurrent LGSOC campaign to raise HCP and patient awareness of AVMAPKI FAKZYNJA CO-PACK (avutometinib; defactinib). The campaign highlights the FDA accelerated approval as the first and only therapy for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who received prior systemic therapy, and offers HCP and patient resources, educational tools, and dedicated websites.
Verastem Oncology (Nasdaq: VSTM) will report first quarter 2026 financial results and host a conference call and webcast on Thursday, May 7, 2026 at 4:30 PM ET.
A live audio webcast with accompanying slides will be available under Events & Presentations on the company investor website, with a replay archived after the event.
Verastem Oncology (NASDAQ: VSTM) reported two-year median follow-up data from the Phase 2 RAMP 201 trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
With a median follow-up of 24.9 months, key efficacy measures remained consistent with the primary analysis: mDoR was 31.1 months in KRAS-mutant patients, mPFS reached 19.6 months in KRAS-mutant patients, and a 12% discontinuation rate due to adverse events was observed. Fifty percent of KRAS-mutated and 30% of KRAS wild-type patients stayed on therapy for over one year. No new safety signals were reported.
Verastem Oncology (Nasdaq: VSTM) granted 141,000 restricted stock units to eleven new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4) on April 2, 2026. The RSUs vest 25% on the one-year hire anniversary, with the remainder vesting quarterly over the following three years, subject to continued service.
Verastem Oncology (Nasdaq: VSTM) announced multiple abstracts accepted for presentation at the AACR Annual Meeting, April 17-22, 2026, including late-breaking data released April 17. Preclinical results show the oral KRAS G12D dual ON/OFF inhibitor VS-7375 produced deeper, sustained tumor regressions versus ON-only RAS inhibitors across pancreatic, lung, and colorectal models.
In KP4 pancreatic xenografts, VS-7375 maintained mean tumor volume ~80 mm by day 30 versus >850 mm for comparator ON-only inhibitors, and VS-7375 showed strong activity combined with PRMT5 inhibition in MTAP-deleted models.